15 results about "Obese subjects" patented technology

The present invention provides nutritional compositions for use in weight loss dietary interventions or in particular weight maintenance after dietary interventions, preferably after low calorie dietary interventions. The nutritional composition comprises one or more amino acids selected from the group consisting of proline, histidine, glycine and / or hydroxyproline, or a combination thereof, which can be used to assist in weight loss in obese subjects that are resistant to weight loss only by means of caloric limiting dietary intervention. In addition, the nutritional composition of the present invention may be used to help maintain the weight loss, particularly after dietary intervention.

Provided herein are compositions, systems, kits, and methods for detecting, in a DNA sample from a subject (e.g., overweight or obese subject), the presence of at least one polymorphism in the Neurobeachin (NBEA) gene. In particular embodiments, once at least one such polymorphism is detected, the subject is treated with, or provided with, a Glucagon-like peptide-1 receptor agonist (GLP-1RA).

One patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention discovers that the cyclic peptide, namely C * LLPAGWV-[N-Me-Leu]-SHLDSYKKREC *, has the effect of reducing the body weight. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can relieve weight gain caused by DIO, so that the weight of the DIO mouse is reduced, and multiple metabolic indexes can be improved. Results show that the COX52-69 cyclic peptide has practical application in weight loss and weight gain prevention processes, and also has reagent application in improvement of some metabolic indexes of obese people.

This application discloses an exercise prescription generation device, method, equipment, and medium, relating to the field of sports health management technology and applied to computer devices. It includes: a feature extraction module that simultaneously collects body composition and muscle strength data from obese subjects, and obtains body composition and muscle strength features through preprocessing and feature extraction; a preliminary generation module that performs hierarchical judgment on the two types of features to determine the obesity type and muscle strength level, and generates a preliminary exercise prescription based on the combination results; a prescription generation module that uses the body-muscle combination index to determine aerobic exercise parameters and determines resistance training parameters based on the muscle strength level, generating a target exercise prescription for the current execution cycle; an exercise review module that obtains the review results after the subject executes the prescription; and a prescription adjustment module that adjusts the prescription based on the review results to obtain the target exercise prescription for the next execution cycle. This effectively solves the problems of single-dimensional exercise prescription assessment, insufficient personalization, inaccurate intensity matching, and lack of quantitative decision-making and dynamic adjustment.

The present invention relates to compounds which are for use in the treatment, alleviation or prevention of obesity and / or a disease, disorder or abnormality associated therewith. In a further embodiment, the compounds are for use in reducing neuroinflammation, reducing microgliosis, and / or improving insulin sensitivity, preferably in an obese subject. In another embodiment, the compounds are for use in the treatment, alleviation or prevention of a disease, disorder or abnormality which is responsive to the modulation of IL-17A and / or IL36G. The compounds are NLRP3 inflammasome pathway inhibitors. In particular, the compounds inhibit the activation of a component of the NLRP3 inflammasome pathway. More particularly, the component of the inflammasome pathway is NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, in particular IL-1 beta and / or IL-18 levels are modulated thereby.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including in overweight or obese subjects. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation or symptoms of menopause, including in overweight or obese subjects.

The application discloses a traditional Chinese medicine formula for treating simple obesity by consolidating the root and removing turbidity, a preparation process and application thereof, and belongs to the technical field of traditional Chinese medicine. The formula is composed of raw astragalus, dried tangerine or orange peel, tuckahoe, fried seed of Chinese yam, gordon euryale seed, Chinese yam, lotus leaf, fried cassia seed, fried hawthorn fruit and cassia bark in a specific ratio and has the effects of benefiting qi, strengthening the spleen, removing turbidity and reducing fat. The granules prepared from the formula contain 10g of crude drug per bag and are taken twice a day after meals for 4 weeks. Clinical preliminary observation shows that the average weight of simple obesity patients is reduced by 2.39kg after taking the medicine, which is obviously better than that of the comparison group (P<0.01), and no obvious adverse reactions are found. It is proved that the formula is safe and effective, and provides a treatment scheme with definite curative effect and high compliance for simple obesity patients.

The utility model relates to the technical field of protection pads, in particular to a health protection pad suitable for obese people, which comprises hip sulcus parts, each hip sulcus part comprises a skin-friendly surface layer, a water absorption layer and an outer breathable bottom layer, and the hip sulcus parts are bilaterally symmetrically arranged and respectively fit the left hip and the right hip of a user. The skin-friendly surface layers and the water absorption layers of the two buttock cleft parts are connected and form raised cleft seam parts, and the cleft seam parts can extend into buttock cleft seams of a user; compared with an existing protection pad, the groove seam part of the protection pad can extend into the hip groove seam of an obese person, no matter whether the user stands or sits down, the protection pad can be attached to the skin of the user all the time and continuously suck sweat or secreta generated around the anus, and it is permanently guaranteed that the crissum and the hip of the user are dry and clean; and meanwhile, the groove seam part extends into the hip groove seam of the user, so that the user can carry out anus lifting action training more easily, and the prevention of perianal diseases is facilitated.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

This invention provides a method of treating hypertension in a hypertensive subject having a body mass index of at least 30, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.

The application relates to the technical field of treatment of centripetal obesity, in particular to a rehabilitation adjusting device for centripetal obesity, which comprises a lying bed and an abdominal fat-burning device, a driving mechanism is arranged below the lying bed, the abdominal fat-burning device comprises a waist supporting mechanism, an abdominal hot massage mechanism and a heating mechanism; the waist supporting mechanism comprises a waist supporting ring, the waist supporting ring is connected to the driving mechanism; the abdominal hot massage mechanism comprises a hot massage roller group and an abdominal covering ring, the abdominal covering ring is hinged to the waist supporting ring, the abdominal covering ring can rotate around the hinge point to form a whole-circular cavity with the waist supporting ring, the cavity is used for accommodating the waist and abdomen of an obese person, the hot massage roller group is arranged on the inner circular surface of the abdominal covering ring and can slide along the inner circular surface of the abdominal covering ring; the heating mechanism is connected to the hot massage roller group and is used for heating the hot massage roller group. The application improves the safety of centripetal obese people in the weight loss and fat reduction process.

A massage chair comprises a frame structure, and an integrated torso support and a seat connected to the frame structure, which may be collapsible. The integrated torso support includes (a) an annular frame portion having a frame opening sized to accommodate a protruding abdomen of a pregnant or obese person, and (b) annular padding configured for removable attachment to the annular frame portion. The annular padding defines an abdominal opening sized to match or reduce the size of the frame opening. The seat is configured with a width sufficient to support a pregnant or obese person in a seated position. A massage chair transport system is also described.

The present disclosure provides combinations for reducing weight and / or preventing weight gain in a subject (e.g., an obese subject) comprising an amylin analog and a GLP-1 receptor agonist As described herein, the GLP-1 receptor agonist and amylin analog can be administered to a subject in the same pharmaceutical composition or in separate pharmaceutical compositions (e.g., via simultaneous or subsequent administration).

The present disclosure provides combinations for reducing weight and / or preventing weight gain in a subject (e.g., an obese subject) comprising three or more (e.g., three or four) of: (i) an amylin analog, (ii) a GLP-1 receptor agonist, (iii) a GIP analog, and (iv) a glucagon analog. As described herein, the combination can be administered to a subject in the same pharmaceutical composition or in separate pharmaceutical compositions (e.g., via concurrent or subsequent administration).

A method of evaluating a subject for a renal condition, wherein the subject is obese or severely obese, and treating the subject based on the evaluation, the method comprising the steps of (1) performing an assay configured to detect a non-benign Kinase D-interacting substrate of 220 kDA (KIDINS220) variant protein in a body fluid sample obtained from the subject; (2) determining that the subject has an elevated risk for end-stage renal disease (ESRD) when one or more non-benign KIDINS220 variants are present in the body fluid sample; and (3) treating the subject having the elevated risk for ESRD with a compatible kidney treatment regimen.